ecrin-mdr-crcClinical2023IPD Sharing (as of May 2023): NoPancreatic Cancer MetastaticColon CancerColorectal Cancer MetastaticColorectal NeoplasmsPancreatic NeoplasmsNeoplasmsPancreatic Cancer MetastaticColon CancerColorectal Cancer MetastaticColorectal NeoplasmsPancreatic NeoplasmsNeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/23708175RetifanlimabPoly ICLCAnti-PD-1Pancreatic Ductal Adenocarcinoma (PDAC)ImmunotherapyCancer VaccinesNeoantigen VaccinesCarboxymethylcellulose SodiumMetastatic colon cancerPoly I-CMetastatic pancreatic cancerECRIN MDRWithdrawnfalseNeoantigen-Targeted Vaccine Combined With Anti-PD-1 Antibody for Patients With Stage IV MMR-p Colon and Pancreatic Ductal CancerPhase 1 study evaluating feasibility, safety, and immune response to a personalized neoantigen vaccine combined with retifanlimab for MMR-p mCRC and mPDAC patients with measurable disease following first-line FOLFIRINOX/FOLFOXIRI (FFX).2023-05-152370817NCT04799431